A Multicenter Trial of Low Dose Gallium Nitrate in Patients with Advanced Paget’S Disease of Bone
Vol. 80. No. 2 Journalof CbnicalEndocrinology and Metabolism Pr’rrnrrd ,,, IJ S.A. CopyrIght0 1995by The EndocrineSociety A Multicenter Trial of Low Dose Gallium Nitrate in Patients with Advanced Paget’s Disease of Bone RICHARD S. BOCKMAN, FRANCOIS WILHELM, ETHEL SIRIS, FREDERICK SINGER, ARTHUR CHAUSMER*, RACHELLE BITTON, JON KOTLER, BARBARA J. BOSCO, DAVID R. EYRE, AND DAVID LEVENSON Department of Medicine, Hospital for Special Surgery and Cornell University Medical College (R.S.B., B.J.B., D.L.), New York, New York 10021; Research and Development, Fujisawa Pharmaceutical Co. (F.W.), Deer-field, Illinois 60015; Columbia University College of Physicians and Surgeons (E.S.), New York, New York 10032; St. John’s Hospital and Health Center, John Wayne Cancer Institute (F.S.1, Santa Monica, California 90404; the Division of Endocrinology, Long Island Jewish Hospital (R.B.1, New Hyde Park, New York 11042; Holy Cross Hospital (J.K.), Ft. Lauderdale, Florida 33008; and the Department of Orthopaedics, University of Washington (D.R.E.), Seattle, Washington 98195 ABSTRACT treated with the 0.5 mg/kg.day dose achieved a 50% or more reduction Gallium nitrate is a potent antiresorptive drug that has been ex- in enzyme activity. The nadir value in hydraxyproline excretion oc- tensively tested in patients with accelerated bone turnover. We have curred at 10 weeks, with mean changes of +9%, -lo%, and ~ 17% for evaluated the effects of this new agent in a pilot multicenter trial of the 0.05, 0.25, and 0.5 mg/kg.day doses, respectively; the difference 49 patients with advanced Paget’s disease of bone.
[Show full text]